PUBLISHER: Mordor Intelligence | PRODUCT CODE: 2116319
PUBLISHER: Mordor Intelligence | PRODUCT CODE: 2116319
According to Mordor Intelligence, veterinary reference laboratory market size in 2026 is estimated at USD 5.97 billion, growing from 2025 value of USD 5.45 billion with 2031 projections showing USD 9.38 billion, growing at 9.45% CAGR over 2026-2031.

This report is Segmented by Service Type (Clinical Chemistry, Immunodiagnostics, Molecular Diagnostics, and Hematology), Application (Pathology, Bacteriology, Virology, and More), Animal Type (Livestock Animals and Companion Animals), and Geography (North America, Europe, Asia-Pacific, and More). The Market Forecasts are Provided in Terms of Value (USD).
Premiums reached USD 4.5 billion in 2024, more than doubling since 2019. Concentrated underwriting among the top ten insurers heightens reimbursement standardization, which in turn lifts acceptance of advanced diagnostics. Veterinary cost inflation of 8.24% reinforces the value proposition of insurance and encourages owners to authorize comprehensive testing without cost anxiety..
AI-enabled platforms such as Zoetis Vetscan Imagyst now deliver cytology, hematology, and urine-sediment readings inside the clinic. Next-generation sequencing cancer panels achieve 92.7% detection accuracy and reveal actionable genomic variants for therapeutic planning frontiersin.org. Multiplex PCR assays detect pathogens at 10 copies/µL while matching national reference standards.
Fully automated systems carry steep capital requirements that many small clinics cannot absorb. Over 80% of China's pet hospitals earn under 2.4 million yuan annually, constraining equipment upgrades. Mobile laboratories and cartridge-based analyzers mitigate barriers but still require upfront hardware investment.
Other drivers and restraints analyzed in the detailed report include:
For complete list of drivers and restraints, kindly check the Table Of Contents.
Immunodiagnostics held 42.98% of the veterinary reference laboratory market in 2025 based on entrenched use in routine screening. Molecular diagnostics, however, is forecast to compound at 10.48% through 2031 on the back of superior pathogen specificity, precision medicine, and shrinking run times. Multiplex PCR panels and next-generation sequencing propel this growth trajectory, supported by falling reagent costs and software automation. Immunodiagnostics' installed base and clinician familiarity sustain its revenue, but competitive pressure steadily diverts high-value oncology and infectious disease testing toward molecular formats.
AI-enhanced cartridge analyzers bring molecular throughput into clinics, shortening result cycles from days to under an hour. Reference laboratories differentiate themselves with whole-genome and liquid biopsy services that inform targeted therapy selection. As test menus broaden, bundled subscription pricing models emerge, anchoring client loyalty and stabilizing cash flows. With these shifts, molecular platforms continue to capture incremental revenue while immunoassay providers add multiplex capability to defend share. Both segments fuel aggregate expansion of the veterinary reference laboratory market.
Clinical pathology accounted for 38.22% of 2025 revenues and remains indispensable for wellness exams and chronic-disease monitoring. Virology's 11.05% CAGR outpaces every other application due to heightened H5N1 surveillance and mandatory influenza testing in livestock. Rapid antigen and RT-PCR panels, validated against national standards, dominate high-volume screening protocols and facilitate trade compliance. Regulatory emphasis on early detection prompts governments to subsidize virology capacity expansion in dairy, poultry, and equine sectors.
Meanwhile, antimicrobial-stewardship programs elevate bacteriology demand, and AI fecal-analysis systems accelerate parasitology adoption. Toxicology testing grows steadier, driven by rising pet exposure to household chemicals. Other niche applications appear as emerging pathogens and novel therapies require specialized assays. Collectively, diverse testing needs reinforce the growth prospects of the veterinary reference laboratory.
Asia-Pacific is the fastest-advancing region at a 12.04% CAGR to 2031. China's pet economy reached 300 billion yuan (USD 41 billion) in 2024 with veterinary care at 28% of spend, though profitability constraints in smaller clinics spur demand for cost-efficient diagnostics. Japanese innovators deploy AI-powered fecal analysis and after-hours tele-health, improving accessibility in an aging-society. Australia attracts multinational investment, as Zoetis expanded vaccine production capacity through a new Melbourne site. Varied regulatory frameworks and uneven infrastructure create a patchwork of opportunities across the region, yet rising household incomes and changing pet-owner behavior support sustained uptake of laboratory services.
North America maintained 38.90% market share in 2025 courtesy of mature practice infrastructure and high pet-care expenditure. FDA Guidance #263, effective June 2024, mandates prescription oversight for antimicrobials, indirectly boosting diagnostic volumes in food animals avma.org. Workforce shortages and declining clinic visits temper momentum, nudging providers toward automation to preserve productivity.
Europe demonstrates steady mid-single-digit expansion supported by regulatory harmonization and recent consolidation. Mars Incorporated completed acquisitions of SYNLAB Vet and Cerba Vet, enhancing test menu breadth and geographic reach . Antimicrobial-stewardship campaigns encourage diagnostics-guided therapy, and established veterinary training programs sustain demand for specialized assays. Emerging markets in the Middle East and Africa remain nascent yet promising, evidenced by the Philippines' PHP 20 million investment in a new veterinary-diagnostic facility pna.gov.ph. Point-of-care platforms offer scalable options for regions lacking extensive laboratory networks, underlining a global convergence toward accessible diagnostics.